Drug Name |
Pazopanib hydrochloride |
Drug ID |
BADD_D01688 |
Description |
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. |
Indications and Usage |
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy) |
Marketing Status |
Prescription; Discontinued |
ATC Code |
L01EX03 |
DrugBank ID |
DB06589
|
KEGG ID |
D05380
|
MeSH ID |
C516667
|
PubChem ID |
11525740
|
TTD Drug ID |
Not Available
|
NDC Product Code |
53104-7727; 76302-012; 63379-093; 66499-0055; 68578-0015; 76055-0050; 54893-0014; 53296-0125; 0078-1077; 62207-977; 0078-0670; 52482-015; 16436-0125; 68554-0058 |
Synonyms |
pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient |